• Arrowhead Pharmaceuticals recently dosed the first subjects in a Phase 1/2a trial of ARO-DIMER-PA, an RNAi therapeutic targeting atherosclerotic cardiovascular disease caused by mixed hyperlipidemia by silencing PCSK9 and APOC3.
• This is the first clinical RNAi candidate designed to simultaneously target two genes in a single molecule, highlighting a new approach to treating residual cardiovascular risk in patients with elevated LDL cholesterol and triglycerides.
• We will now explore how this first-in-human dual-gene RNAi trial in cardiovascular disease may influence Arrowhead Pharmaceuticals' broader investment narrative.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

What Is Arrowhead Pharmaceuticals' Investment Narrative?

To own Arrowhead, you have to believe in RNAi as a platform company and accept a bumpy path to monetizing that science. The recent ARO-DIMER-PA first-in-human trial is more important for Arrowhead’s long-term story than its near-term numbers, reinforcing the idea that the TRiM platform could support differentiated, multi-gene cardiometabolic drugs beyond partnered products like REDEMPLO. In the short term, though, the key catalysts still look familiar: clinical readouts across the pipeline, any new partnerships or milestones that can add to the US$829.45 million revenue base, and how the recent US$200 million equity raise is deployed. The biggest risks remain execution and financing in an unprofitable, high-valuation business that has already seen a very large 1-year total return and recent insider selling.

However, there is an important financing and dilution risk here that investors should not ignore. Arrowhead Pharmaceuticals' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates span from roughly US$0.33 to about US$140 per share, underlining how far apart individual views can be. Set against a company that remains unprofitable, relies on follow-on equity offerings and is advancing a first-in-class dual-gene RNAi program, this spread gives you a reason to compare several perspectives before deciding how Arrowhead might fit into your portfolio.

Explore 3 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth less than half the current price!

Build Your Own Arrowhead Pharmaceuticals Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.